JPRN-UMIN000003529已完成2 期
Phase II study of neoadjuvant chemotherapy with L-OHP and S-1 for locally advanced colorectal cancer with lymph node metastases - Phase II study of neoadjuvant chemotherapy with L-OHP and S-1 for locally advanced colorectal cancer with lymph node metastases
iigata Colorectal cancer Chemotherapy Study Group (NCCSG)0 个研究点目标入组 35 人开始时间: 2010年4月26日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old(—)
- 性别
- All
入选标准
- 未提供
排除标准
- •1)with sensory neuropathy 2)with active double cancer 3)had active infection disease (over 38.0 degree) 4)with sever diarrhea 5)had serious complication (e.g. interstitialpneumonia, or pulmonary fibrosis, kidney injury, hepatic failure, uncontrolled diabetes mellitus, uncontrolled hypertension) 6)with previous serious drug hyperseneitivity 7)with significant abnormal electrocardiogram or cardiovascular disease (e.g. heart failure, myocardial infarction, angina pectoris) 8)with myelosupression 9)with chickenpox 10)had pleural effusion or ascites which need therapy 11)receiving Flucytosine 12)Pregnant or lactating women, women who are capable of pregnancy, intend to get pregnant or men who want to get their partners pregnant 13)had a previous serious drug allergies 14).clinical evidence of CNS metastases or had a history of brain metastasis 15)were systemically-administered of steroids 16)with jaundice 17)except referred to above, physician in charge of this trial gave a diagnosis the patient who can not joint this trail for the safety.
研究者
相似试验
已完成
2 期
Phase II study of neoadjuvant chemotherapy with L-OHP and S-1 for locally advanced rectal cancer (NCCSG-09)locally advanced rectal cancerJPRN-UMIN000009764iigata Colorectal cancer Chemotherapy Study Group (NCCSG)35
进行中(未招募)
不适用
Phase II study of Neo-adjuvant chemotherapy with letrozole in patients with estrogen receptor positive/HER-2 negative breast cancerKCT0008323ational Cancer Center114
已完成
不适用
PhaseII study of neoadjuvant chemotherapy with the nab Paclitaxel And Trastuzumab followed by FEC for the HER2-positive resectable primary breast cancerHER2 positive resectable primary breast cancerJPRN-UMIN000008465Osaka Breast Cancer Chemo-Endocrine Therapy Study Group30
招募中
2 期
Phase II study of the neoadjuvant chemotherapy of GEM/nab-PTX for biological borderline-resectable pancreatic cancerC535836pancreatic cancerJPRN-jRCT1041230068Ebata Tomoki50
已完成
不适用
Phase II study of neoadjuvant chemotherapy with the FEC followed by weekly nab-Paclitaxel(nanoparticle albumin-bound paclitaxel) for the operable breast cancer (KSCOG-BC07)Breast CancerJPRN-UMIN000010504Department of Surgery Kurume University School of Medicine30
